



(51) International Patent Classification:

C07K 16/24 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2023/068621

(22) International Filing Date:

16 June 2023 (16.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/353,367 17 June 2022 (17.06.2022) US
63/462,822 28 April 2023 (28.04.2023) US
63/469,167 26 May 2023 (26.05.2023) US

(71) Applicant: APOGEE BIOLOGICS, INC. [US/US]; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US).

(72) Inventors: SHAHEEN, Hussam H.; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US). THOMPSON, Kenneth Evan; 221 Crescent St.,

Building 17, Suite 102B, Waltham, Massachusetts 02453 (US). HARWIN, Peter; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US). KISE-LAK, Tomas; 221 Crescent St., Building 17, Suite 102B, Waltham, Massachusetts 02453 (US).

(74) Agent: GUSTAFSON, Megan; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th Fl., Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE




FIG. 1

(57) Abstract: Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.